UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
INFECTIOUS DISEASE & VACCINES

bioMerieux

B

bioMerieux

Infectious Disease & VaccinesMarcy-l'Etoile, France
Visit Website

About bioMerieux

bioMerieux pioneered the concept of in vitro diagnostics as a standalone medical discipline, and today stands as one of the world's leading independent companies dedicated entirely to that field. Founded in 1963 in Lyon, France by Marcel Merieux and listed on Euronext Paris (ticker: BIM), the company has spent more than six decades developing diagnostic solutions that help clinicians identify infectious diseases, detect contamination in food and pharmaceutical manufacturing, and guide treatment decisions at the point of care.

Infectious Disease & Microbiology Focus

The company's core expertise lies in microbiology and infectious disease diagnostics. Its VITEK system, a flagship automated microbiology platform, is widely used in clinical laboratories across the globe to identify pathogens and determine antibiotic susceptibility profiles. Alongside VITEK, bioMerieux offers the BIOFIRE FilmArray syndromic testing panels, which deliver rapid multiplex PCR results for respiratory, gastrointestinal, meningitis and bloodstream infections from a single sample within roughly an hour. These platforms are deeply embedded in hospital and reference laboratory workflows worldwide.

Industrial Microbiology & Quality Control

Beyond clinical settings, bioMerieux serves the food safety and pharmaceutical quality control markets through its industrial microbiology portfolio. Solutions such as the VIDAS immunoassay platform and TEMPO enumeration systems help manufacturers verify the microbiological safety of products before they reach consumers or patients. This dual presence across clinical and industrial sectors distinguishes the company from many purely pharmaceutical peers.

Headquartered in Marcy-l'Etoile, near Lyon, France, bioMerieux operates in more than 160 countries and employs tens of thousands of people globally. The Merieux family retains a controlling interest, underpinning a long-term, science-led strategic vision rather than purely short-term financial priorities. The company invests significantly in research and development, with a particular emphasis on molecular biology, immunoassay technology and digital health solutions that connect diagnostic data to clinical decision support.

Further information is available at biomerieux.com.

Similar Companies

More in Infectious Disease & Vaccines

A

AN2 Therapeutics

Grounded in a proprietary boron chemistry platform, AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology, with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases, particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

View profile
R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
I

Illumina

Illumina is the company that made whole-genome sequencing a routine laboratory tool, transforming what was once a decade-long, billion-dollar undertaking into an everyday clinical and research workflow. Founded in 1998 and headquartered in San Diego, California, Illumina develops and manufactures sequencing and array-based instruments, reagents, and informatics software used by researchers, hospitals, and public health agencies in more than 160 countries. Sequencing Platforms & Instruments The company's portfolio spans a wide range of output scales, from the compact iSeq 100 designed for low-throughput clinical applications to the NovaSeq X Series, capable of sequencing multiple human genomes per run. This breadth allows Illumina to serve single-investigator labs and national genomics programmes alike. The DRAGEN Bio-IT Platform provides on-board secondary analysis, accelerating the path from raw sequence data to actionable variant calls. Clinical Genomics & Oncology Applications Illumina's technology underpins a substantial portion of global next-generation sequencing activity in oncology, inherited disease, reproductive health, and infectious disease surveillance. Its instruments and kits are widely used for companion diagnostic development, rare disease diagnosis, non-invasive prenatal testing, and cancer genomic profiling. The company has also invested in multi-cancer early detection through its Grail subsidiary, which operates the Galleri liquid biopsy test. Listed on NASDAQ under the ticker ILMN, Illumina is a large-cap life science tools company with revenues consistently in the multi-billion-dollar range. Its customer base includes academic research centres, pharmaceutical and biotechnology companies, contract research organisations, and national health services. The company has been central to landmark population genomics initiatives, including partnerships with the UK Biobank and various national sequencing programmes launched during the COVID-19 pandemic for viral surveillance. Illumina operates manufacturing sites in San Diego and Singapore, with commercial offices across North America, Europe, and Asia-Pacific. Research and development investment has remained a defining feature of its business model, with ongoing work on short-read chemistry improvements and emerging long-read sequencing capabilities. Further information is available at illumina.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy